EUVIMEDEUVIMED entdecken
Open Access

ADRA2A promotes the classical/progenitor subtype and reduces disease aggressiveness of pancreatic cancer

Paloma Moreno, Yuuki Ohara iD, Amanda J Craig, Huaitian Liu, Shouhui Yang iD, Tiffany H Dorsey, Lin Zhang, Gatikrushna Panigrahi, Helen Cawley, Azadeh Azizian, Jochen Gaedcke, Michael Ghadimi und 2 weitere

Carcinogenesis · 2024

DOI: 10.1093/carcin/bgae056 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Carcinogenesis, 2024. Verfasst von Paloma Moreno und 13 weiteren Autor:innen. Beteiligte Einrichtung: Pancreatic Cancer Section, Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, …. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal, Receptors, Adrenergic, alpha-2, Gene Expression Regulation, Neoplastic. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural Program of Center for Cancer Research, The National Cancer Institute, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pancreatic ductal adenocarcinoma (PDAC) manifests diverse molecular subtypes, including the classical/progenitor and basal-like/squamous subtypes, with the latter known for its aggressiveness. We employed integrative transcriptome and metabolome analyses to identify potential genes contributing to the molecular subtype differentiation and its metabolic features. Our comprehensive analysis revealed that adrenoceptor alpha 2A (ADRA2A) was downregulated in the basal-like/squamous subtype, suggesting its potential role as a candidate suppressor of this subtype. Reduced ADRA2A expression was significantly associated with a high frequency of lymph node metastasis, higher pathological grade, advanced disease stage, and decreased survival among PDAC patients. In vitro experiments demonstrated that ADRA2A transgene expression and ADRA2A agonist inhibited PDAC cell invasion. Additionally, ADRA2A-high condition downregulated the basal-like/squamous gene expression signature, while upregulating the classical/progenitor gene expression signature in our PDAC patient cohort and PDAC cell lines. Metabolome analysis conducted on the PDAC cohort and cell lines revealed that elevated ADRA2A levels were associated with suppressed amino acid and carnitine/acylcarnitine metabolism, which are characteristic metabolic profiles of the classical/progenitor subtype. Collectively, our findings suggest that heightened ADRA2A expression induces transcriptome and metabolome characteristics indicative of classical/progenitor subtype with decreased disease aggressiveness in PDAC patients. These observations introduce ADRA2A as a candidate for diagnostic and therapeutic targeting in PDAC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsCarcinoma, Pancreatic DuctalReceptors, Adrenergic, alpha-2Gene Expression Regulation, NeoplasticHumansCell Line, TumorMaleFemaleCarnitineTranscriptomeNeoplasm InvasivenessMetabolomeLymphatic MetastasisMiddle AgedPrognosis

Stichwörter der Autor:innen

adrenoceptor alpha 2Acarnitine/acylcarnitinemetabolic subtypemolecular subtypepancreatic ductal adenocarcinoma

Substanzen

ADRA2A protein, humanReceptors, Adrenergic, alpha-2Carnitineacylcarnitine

Autor:innen und Institutionen

  • Pancreatic Cancer Section, Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, United States.
  • Laboratory of Human Carcinogenesis, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, United States.
  • Städtisches Klinikum Karlsruhe, Moltkestraße 90, 76133 Karlsruhe, Germany.
  • Department of General, Visceral and Pediatric Surgery, University Medical Center Göttingen, Robert-Koch-Straße 40, 37075 Göttingen, Germany.
  • Division of General and Oncologic Surgery, University of Maryland School of Medicine, Baltimore, MD 21201, United States.
  • Division of Surgical Oncology, Department of Surgery, Thomas Jefferson University, Philadelphia, PA 19107, United States.

ORCID-Profile: Yuuki Ohara, Shouhui Yang, S Perwez Hussain

Förderung

  • Intramural Program of Center for Cancer Research
  • The National Cancer Institute
  • NIH HHS
  • National Institutes of Health

Zitieren

APA

Moreno, P., Ohara, Y., Craig, A. J., Liu, H., Yang, S., Dorsey, T. H., Zhang, L., Panigrahi, G., Cawley, H., Azizian, A., Gaedcke, J., Ghadimi, M., Hanna, N., & Hussain, S. P. (2024). ADRA2A promotes the classical/progenitor subtype and reduces disease aggressiveness of pancreatic cancer. Carcinogenesis. https://doi.org/10.1093/carcin/bgae056

Vancouver

Moreno P, Ohara Y, Craig AJ, Liu H, Yang S, Dorsey TH, et al. ADRA2A promotes the classical/progenitor subtype and reduces disease aggressiveness of pancreatic cancer. Carcinogenesis. 2024. doi:10.1093/carcin/bgae056

BibTeX
@article{Moreno2024,
  author = {Moreno, Paloma and Ohara, Yuuki and Craig, Amanda J and Liu, Huaitian and Yang, Shouhui and Dorsey, Tiffany H and Zhang, Lin and Panigrahi, Gatikrushna and Cawley, Helen and Azizian, Azadeh and Gaedcke, Jochen and Ghadimi, Michael and Hanna, Nader and Hussain, S Perwez},
  title = {ADRA2A promotes the classical/progenitor subtype and reduces disease aggressiveness of pancreatic cancer},
  journal = {Carcinogenesis},
  year = {2024},
  doi = {10.1093/carcin/bgae056}
}
Kostenlos starten →